Skip to content

Solid Biosciences

US · SLDB #3476 by market cap Listed 2018
6.25 -0.19 -2.95%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 6.28 -2.48%
After-hours 6.25 0.00%
11.155.476.252026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on SLDB?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +4.4% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 12.4% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability F

How much profit the business keeps from each dollar of sales and capital.

Operating margin -1,226.5% Better than 3%
Net margin -1,062.3% Better than 2%
Return on equity -109.9% Better than 5%
Return on invested capital -101.7% Better than 2%
Momentum C

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -32.8% Better than 16%
6-month return -5.6% Better than 46%
12-month return (ex latest month) 31.7% Better than 71%
Distance below 52-week high 45.4% Better than 23%
Financial Health B

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 6.1x Better than 89%
Debt to assets 9.1% Better than 71%
Interest coverage -365.8x Better than 3%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 188.0% Better than 94%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -8.63%
1M -2.34%
3M -31.32%
6M -3.40%
YTD +10.82%
1Y +40.13%
3Y +162.61%
5Y -79.06%

Key statistics

Price & volume

Prev close
6.44
Open
6.34
Day range
6.20 - 6.53
Avg price
6.29
Volume
1.56M
Turnover
9.81M
Amplitude
5.20%
52-week range
4.65 - 11.45

Valuation

P/E
-3.14
P/E (TTM)
-3.55
P/B
2.04
EPS
-1.99
Net profit
-222.10M
Net assets
342.09M

Share structure

Market cap
697.57M
Float cap
395.50M
Shares out
111.61M
Float shares
63.28M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2018-01-25
52-week range 24% of range
4.65 11.45

45.4% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-8.98M net over the window

Short interest

Shares short
13.30M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Solid Biosciences (SLDB)?

Solid Biosciences last traded at 6.25. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Solid Biosciences's market cap?

About 697.57M.

What is the P/E ratio of Solid Biosciences?

The trailing twelve-month P/E is -3.55. The Valuation tab shows it against the stock's own five-year range.

Does Solid Biosciences pay a dividend?

Solid Biosciences does not currently pay a regular dividend.

Is Solid Biosciences a buy according to analysts?

The consensus of 11 analysts is a Buy rating, with an average 12-month price target of 18.00, which implies 188.0% upside from the current price. This is not investment advice.

What is Solid Biosciences's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Solid Biosciences a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Solid Biosciences discussion 0 comments

Add a comment